SEC Form 4 · accession 0001193125-26-384391
Pyxis Oncology, Inc. · PYXS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Civik
Officer — CEO & Chairman of the Board · Director
Period of report
Sep 4, 2026
Accepted (ET)
Sep 8, 2026 · 7:41 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001782223
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.89 | Sep 4, 2026 | A | 2,503,050 | A | — | Sep 4, 2036 | Common Stock | 2,503,050 | 2,503,050 | D |
Explanation of responses
- F1The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of September 4, 2026 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.